Eli Lilly (NYSE: LLY) has started construction on a US$6.5b manufacturing facility in Houston to produce its oral GLP-1 drug ...
Eli Lilly is trying to catch up in the GLP-1 pill market to Novo, which got a head start in the space.
Sign-ups for Medicare’s GLP-1 coverage plan keep expanding, and Eli Lilly is dominating the market with 70% share, the company’s CEO David Ricks said. | Sign-ups for Medicare’s GLP-1 coverage plan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results